2010
Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis
Friedland G. Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 55: s37-s42. PMID: 21045598, PMCID: PMC4505738, DOI: 10.1097/qai.0b013e3181f9c0b6.Peer-Reviewed Original ResearchConceptsHepatitis CDrug interactionsDrug usersDrug useActive screening programsSpecial clinical challengeIsoniazid preventive therapySubstance abusersInjection drug usePharmacodynamic drug interactionsDrug-resistant organismsTreatment of tuberculosisInfectious disease comorbiditiesHIV/AIDSPreventive therapyTreatment initiationComorbid conditionsMedication adherenceHIV pandemicScreening programClinical challengeClinician expertiseTherapeutic successClinical consequencesInfection controlTreatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. The Lancet 2010, 376: 367-387. PMID: 20650518, PMCID: PMC4855280, DOI: 10.1016/s0140-6736(10)60829-x.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAntipsychotic AgentsAntitubercular AgentsAntiviral AgentsBacterial InfectionsComorbidityCriminal LawDrug InteractionsDrug Resistance, BacterialEvidence-Based MedicineHepatitis, Viral, HumanHIV InfectionsHumansMedication AdherenceMental DisordersNarcoticsPrisonersSubstance-Related DisordersTuberculosisConceptsSubstance use disordersDrug usersAntiretroviral therapyViral hepatitisHIV treatmentHealth of HIVPharmacokinetic drug interactionsSubstance use comorbiditiesMedication-assisted therapyEvidence-based treatmentsDrug-resistant strainsHealth-related outcomesHealth service deliveryInfectious complicationsMultiple comorbiditiesHIV infectionPsychiatric comorbidityPoor adherenceClinical managementCardiovascular diseaseInadequate prescriptionCongregate settingsDrug interactionsComorbiditiesHIV
2007
Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean changeInteraction between buprenorphine and atazanavir or atazanavir/ritonavir
McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug And Alcohol Dependence 2007, 91: 269-278. PMID: 17643869, PMCID: PMC3272856, DOI: 10.1016/j.drugalcdep.2007.06.007.Peer-Reviewed Original ResearchConceptsAtazanavir/ritonavirDrug interactionsMini-Mental State ExaminationOpioid partial agonistPharmacokinetics of atazanavirPharmacokinetics of buprenorphineHIV-negative volunteersEffects of buprenorphineConcentrations of buprenorphineAdverse drug interactionsProtease inhibitor atazanavirAntiretroviral administrationBuprenorphine doseHIV diseaseBuprenorphine treatmentHIV medicationsBuprenorphine/Opioid dependencePharmacodynamic effectsRitonavir concentrationsHealthy controlsOpioid addictionBuprenorphineState ExaminationAtazanavir
2005
The Role of Substance Abuse in HIV Disease Progression: Reconciling Differences from Laboratory and Epidemiologic Investigations
Kapadia F, Vlahov D, Donahoe RM, Friedland G. The Role of Substance Abuse in HIV Disease Progression: Reconciling Differences from Laboratory and Epidemiologic Investigations. Clinical Infectious Diseases 2005, 41: 1027-1034. PMID: 16142670, DOI: 10.1086/433175.Peer-Reviewed Original ResearchConceptsHIV disease progressionDisease progressionEpidemiologic investigationsHIV/AIDS epidemicUse of licitEpidemiological studiesSubstance abuseStudy designDrug abuseAIDS epidemicCareful evaluationReview of findingsProgressionIllicit drugsLaboratory-based studiesMethodological strengthsFindingsAbuseMixed results
2004
Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical servicesDrug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir
McCance‐Katz E, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir. American Journal On Addictions 2004, 13: 163-180. PMID: 15204667, DOI: 10.1080/10550490490436037.Peer-Reviewed Original ResearchConceptsDrug interactionsMetabolite exposureClinical pharmacology studiesInjection drug usersNelfinavir concentrationsOpiate medicationsOpiate therapyMethadone exposureAntiretroviral medicationsHIV outcomesDay study periodPharmacology studiesDrug usersMethadoneNelfinavirLAAMStudy periodMedicationsMinimal overall changeProtease inhibitorsExposureToxicityOverall changeAntiretroviralsOpioids
1995
Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use.
Hartel D, Schoenbaum E, Selwyn P, Kline J, Davenny K, Klein R, Friedland G. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. American Journal Of Public Health 1995, 85: 83-88. PMID: 7832267, PMCID: PMC1615273, DOI: 10.2105/ajph.85.1.83.Peer-Reviewed Original ResearchMeSH KeywordsAdultCocaineCross-Sectional StudiesFemaleHeroin DependenceHumansMaleMethadoneSubstance Abuse DetectionSubstance-Related DisordersConceptsMethadone maintenance treatmentHeroin useMaintenance treatmentHigh-dose methadone maintenanceCocaine useMethadone dosage levelsNonusers of cocaineMethadone doseLogistic regression statistical modelMethadone dosageMethadone patientsTreatment complianceMethadone maintenanceIndependent associationTreatment durationCross-sectional samplePatientsAlcohol useDosage levelsCocaine usersSocioeconomic factorsTreatmentFurther investigationCocaineNonusers
1989
Risk Factors for Human Immunodeficiency Virus Infection in Intravenous Drug Users
Schoenbaum E, Hartel D, Selwyn P, Klein R, Davenny K, Rogers M, Feiner C, Friedland G. Risk Factors for Human Immunodeficiency Virus Infection in Intravenous Drug Users. New England Journal Of Medicine 1989, 321: 874-879. PMID: 2770823, DOI: 10.1056/nejm198909283211306.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionIntravenous drug usersPercentage of injectionsRisk factorsHIV antibodiesDrug usersIntravenous drugsVirus infectionSex partnersSeroprevalence of HIVIndependent risk factorOnly risk factorMethadone treatment programsNumber of injectionsNon-Hispanic whitesHeterosexual sex partnersHIV infectionLast injectionUsed needlesHigh seroprevalenceDrug useShooting galleriesHIVInfectionProspective Study of Human Immunodeficiency Virus Infection and Pregnancy Outcomes in Intravenous Drug Users
Selwyn P, Schoenbaum E, Davenny K, Robertson V, Feingold A, Shulman J, Mayers M, Klein R, Friedland G, Rogers M. Prospective Study of Human Immunodeficiency Virus Infection and Pregnancy Outcomes in Intravenous Drug Users. JAMA 1989, 261: 1289-1294. PMID: 2915455, DOI: 10.1001/jama.1989.03420090053030.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionPregnancy outcomesDrug usersVirus infectionFemale intravenous drug usersHIV disease statusSeropositive pregnant womenAdverse pregnancy outcomesAsymptomatic HIV infectionNeonatal complicationsEctopic pregnancyPreterm deliveryHIV antibodiesBreech presentationHIV infectionSymptomatic diseaseBacterial pneumoniaHIV statusPregnant womenProspective studyWeight birthsAdditional womenMethadone programsA Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus Infection
Selwyn P, Hartel D, Lewis V, Schoenbaum E, Vermund S, Klein R, Walker A, Friedland G. A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1989, 320: 545-550. PMID: 2915665, DOI: 10.1056/nejm198903023200901.Peer-Reviewed Original ResearchConceptsHIV-seropositive subjectsIntravenous drug usersPositive PPD testHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionActive tuberculosisPPD testDrug usersSeronegative subjectsSeropositive subjectsTuberculous infectionSkin testingVirus infectionHIV-seronegative intravenous drug usersHIV-seronegative subjectsLatent tuberculous infectionRisk of tuberculosisTuberculin skin testingCases of tuberculosisMethadone maintenance programHIV antibodiesHIV-seropositiveHIV infectionProspective studyProtein derivative (PPD) tuberculin
1988
Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS
Selwyn P, Feingold A, Hartel D, Schoenbaum E, Alderman M, Klein R, Friedland G. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988, 2: 267-272. PMID: 3140832, DOI: 10.1097/00002030-198808000-00005.Peer-Reviewed Original ResearchConceptsIntravenous drug usersIntravenous drug useBacterial pneumoniaHIV infectionDrug usersDrug useActive intravenous drug useCommunity-acquired bacterial pneumoniaCumulative yearly incidenceMethadone maintenance programSeronegative subjectsSeropositive patientsSeropositive subjectsStudy entryOpportunistic infectionsYearly incidencePneumoniaHemophilus influenzaeStreptococcus pneumoniaeSeropositivesHIVAIDSInfectionStudy periodIncidenceAIDS and Compassion
Friedland G. AIDS and Compassion. JAMA 1988, 259: 2898-2899. PMID: 3367458, DOI: 10.1001/jama.1988.03720190066034.Peer-Reviewed Original Research
1987
Transmission of the Human Immunodeficiency Virus
Friedland G, Klein R. Transmission of the Human Immunodeficiency Virus. New England Journal Of Medicine 1987, 317: 1125-1135. PMID: 3309656, DOI: 10.1056/nejm198710293171806.Peer-Reviewed Original ResearchInability to predict diagnosis in febrile intravenous drug abusers.
Marantz P, Linzer M, Feiner C, Feinstein S, Kozin A, Friedland G. Inability to predict diagnosis in febrile intravenous drug abusers. Annals Of Internal Medicine 1987, 106: 823-8. PMID: 3579068, DOI: 10.7326/0003-4819-106-6-823.Peer-Reviewed Original ResearchConceptsIntravenous drug abusersFinal diagnosisEmergency roomTrivial illnessDrug abusersDistribution of diseaseInfective endocarditisConsecutive admissionsPhysicians' predictionsClinical dataDiagnostic predictionClinical informationPredictive valuePatientsDiagnosisIllnessLaboratory dataEndocarditisAbusersHospitalizationPneumoniaAdmissionFeverDiseaseThe Acquired Immunodeficiency Syndrome: General Overview
Friedland G. The Acquired Immunodeficiency Syndrome: General Overview. International Journal Of Neuroscience 1987, 32: 677-686. PMID: 3647936, DOI: 10.3109/00207458709043322.Peer-Reviewed Original Research
1985
Intravenous drug abusers and the acquired immunodeficiency syndrome (AIDS). Demographic, drug use, and needle-sharing patterns.
Friedland G, Harris C, Butkus-Small C, Shine D, Moll B, Darrow W, Klein R. Intravenous drug abusers and the acquired immunodeficiency syndrome (AIDS). Demographic, drug use, and needle-sharing patterns. JAMA Internal Medicine 1985, 145: 1413-7. PMID: 3875327, DOI: 10.1001/archinte.145.8.1413.Peer-Reviewed Original ResearchConceptsDrug abuser patientsIntravenous drug abusersDrug abusersImmunodeficiency syndromeNeedle sharingHomosexual menPutative AIDS agentPercent of patientsEvidence of AIDSBlood-borne routeDrug use patternsDrug use practicesARC patientsSexual habitsDrug usePatientsShooting galleriesSpread of AIDSAIDS agentsAIDSAIDS transmissionMale homosexualsDemographic characteristicsAbusersSyndrome
1984
Oral Candidiasis in High-Risk Patients as the Initial Manifestation of the Acquired Immunodeficiency Syndrome
Klein R, Harris C, Small C, Moll B, Lesser M, Friedland G. Oral Candidiasis in High-Risk Patients as the Initial Manifestation of the Acquired Immunodeficiency Syndrome. New England Journal Of Medicine 1984, 311: 354-358. PMID: 6738653, DOI: 10.1056/nejm198408093110602.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultCandidiasis, OralFemaleHomosexualityHumansLymphatic DiseasesLymphocytesMaleRiskSarcoma, KaposiSubstance-Related DisordersConceptsT4/T8 ratioOral candidiasisT8 ratioImmunodeficiency syndromeOpportunistic infectionsHigh-risk patientsMajor opportunistic infectionIntravenous drug abusersAcquired Immunodeficiency SyndromeSerious opportunistic infectionsGeneralized lymphadenopathyInitial manifestationSimilar patientsKaposi's sarcomaHigh riskPatientsHealthy adultsCandidiasisLymphadenopathyBisexual menAIDSSarcomaSyndromeInfectionMonths
1983
Acquired Immunodeficiency Syndrome Ophthalmic Manifestations in Ambulatory Patients
Rosenberg P, Uliss A, Friedland G, Harris C, Small C, Klein R. Acquired Immunodeficiency Syndrome Ophthalmic Manifestations in Ambulatory Patients. Ophthalmology 1983, 90: 874-878. PMID: 6314220, DOI: 10.1016/s0161-6420(83)80010-4.Peer-Reviewed Original ResearchConceptsAmbulatory patientsIntravenous drug abuseCotton wool spotsEpidemiology of AIDSCytomegalovirus retinitisOcular findingsOcular involvementOphthalmic manifestationsImmunodeficiency syndromePatientsMajor manifestationsDrug abuseManifestationsRetinitisSyndromeOphthalmologistsEpidemiologyAIDSFindingsImmunodeficiency in Female Sexual Partners of Men with the Acquired Immunodeficiency Syndrome
Harris C, Small C, Klein R, Friedland G, Moll B, Emeson E, Spigland I, Steigbigel N. Immunodeficiency in Female Sexual Partners of Men with the Acquired Immunodeficiency Syndrome. New England Journal Of Medicine 1983, 308: 1181-1184. PMID: 6221192, DOI: 10.1056/nejm198305193082001.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultCoitusFemaleHumansImmunoglobulinsMaleSubstance-Related DisordersT-Lymphocytes, Helper-InducerT-Lymphocytes, RegulatoryConceptsFemale sexual partnersMale patientsImmunodeficiency syndromeSexual partnersProdrome of AIDSSuppressor T cellsAcquired Immunodeficiency SyndromeImmunologic abnormalitiesProdromal illnessBiologic agentsT cellsDrug abusersHealthy adultsSyndromeCurrent outbreakDecreased ratioWomenPatientsHeterosexual menIllnessAbnormalitiesAIDSMenLymphadenopathyLymphopenia